Innoviva to Participate in the UBS Global Healthcare Conference
Innoviva to Participate in the UBS Global Healthcare Conference
Innoviva is a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets. Innoviva's royalty portfolio includes respiratory assets partnered with Glaxo Group Limited ("GSK"). Innoviva is entitled to receive royalties from GSK on sales of RELVAR/BREO ELLIPTA and ANORO ELLIPTA. Innoviva's other innovative healthcare assets include infectious disease and critical care assets stemming from acquisitions of Entasis Therapeutics, including XACDURO (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use approved for the treatment of adults with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible strains of Acinetobacter baumannii-calcoaceticus complex and the investigational zoliflodacin currently being developed for the treatment of uncomplicated gonorrhea, and La Jolla Pharmaceutical Company, including GIAPREZA (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock and XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults.BURLINGAME, Calif.--(BUSINESS WIRE)--Nov. 12, 2024--Innoviva, Inc. (NASDAQ: INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets, today announced that management will participate in a fireside chat at the UBS Global Healthcare Conference in Ranch Palos Verdes, CA on Wednesday, November 13, 2024 at 10:15 a.m. Pacific Time.
加利福尼亞州伯林蓋姆--(商業通訊)--2024年11月12日--Innoviva, Inc.（納斯達克：INVA）（「Innoviva」或「公司」），是一家多元化控股公司，擁有核心的特許權使用費投資組合，領先的重症護理和傳染病平台稱爲Innoviva Specialty Therapeutics（「IST」），以及在醫療健康資產方面的戰略投資組合，今天宣佈管理層將參加於2024年11月13日太平洋時間上午10:15在加州蘭奇帕洛斯弗迪斯舉行的瑞銀全球醫療保健會議上的爐邊談話。
A live webcast of the fireside chat can be accessed under "Events & Presentations" in the Investor Relations section of the Company's website at . The webcast will be available for replay for 90 days following the event.
可以在公司的官方網站的「投資者關係」部分的「事件與演示」下訪問爐邊談話的現場直播網絡廣播。該網絡廣播將在活動結束後可進行90天的回放。
About Innoviva
關於Innoviva
Innoviva is a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets. Innoviva's royalty portfolio includes respiratory assets partnered with Glaxo Group Limited ("GSK"). Innoviva is entitled to receive royalties from GSK on sales of RELVAR/BREO ELLIPTA and ANORO ELLIPTA. Innoviva's other innovative healthcare assets include infectious disease and critical care assets stemming from acquisitions of Entasis Therapeutics, including XACDURO (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use approved for the treatment of adults with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible strains of Acinetobacter baumannii-calcoaceticus complex and the investigational zoliflodacin currently being developed for the treatment of uncomplicated gonorrhea, and La Jolla Pharmaceutical Company, including GIAPREZA (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock and XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults.
Innoviva是一家多元化控股公司，擁有核心的特許權使用費投資組合，領先的重症護理和傳染病平台稱爲Innoviva Specialty Therapeutics（「IST」），以及在醫療健康資產方面的戰略投資組合。Innoviva的特許權使用費投資組合包括與格蘭素史克集團（「GSK」）合作的呼吸道資產。Innoviva有權從GSk獲得RELVAR/BREO ELLIPTA和ANORO ELLIPTA的銷售特許權使用費。Innoviva的其他創新醫療資產包括來自對Entasis Therapeutics的收購的傳染病和重症護理資產，包括XACDURO（注射用舒巴坦；注射用杜洛巴坦），已聯合包裝用於經批准的以靜脈注射治療成人由可感染的阿西奈特巴克特複雜物引起的醫院獲得性細菌性肺炎和呼吸機相關性細菌性肺炎，以及目前正在開發的無併發症淋病治療的研究性藥物zoliflodacin，和拉霍亞製藥公司，其中包括GIAPREZA（血管收縮素II），批准用於提高成人在出現膿毒症或其他分佈性休克情況下的血壓以及XERAVA（eravacycline），用於治療成人的複雜腹腔感染。
ANORO, RELVAR and BREO are trademarks of the GSK group of companies.
ANORO、RELVAR和BREO是GSk集團公司的商標。
View source version on businesswire.com:
在businesswire.com上查看源版本：
Innoviva, Inc.
David Patti
Corporate Communications
(908) 421-5971
david.patti@inva.com
Innoviva，Inc。
大衛·帕蒂
企業通訊
(908) 421-5971
david.patti@inva.com
Investors and Media:
Argot Partners
(212) 600-1902
innoviva@argotpartners.com
投資者和媒體:
阿哥特合夥人。
（212）600-1902
innoviva@argotpartners.com
Source: Innoviva, Inc.
來源：innoviva公司。
譯文內容由第三人軟體翻譯。
